MEDICATION PRESCRIBING PATTERN FOR CHRONIC KIDNEY DISEASE PATIENTS UNDERGOING MAINTENANCE HAEMODIALYSIS: A PROSPECTIVE OBSERVATIONAL STUDY.
Main Article Content
Keywords
Chronic kidney disease, hemodialysis, medication adherence, prescribing patterns
Abstract
Background: Chronic kidney disease (CKD) results from various kidney disorders affecting structure and function due to diverse pathophysiological processes. It poses a global health threat, particularly in developing countries, with increasing incidence, poor outcomes, and high treatment costs. CKD is associated with comorbidities such as hypertension and diabetes, identified as major risk factors. This study aims to investigate medication prescribing patterns in hypertensive CKD patients undergoing maintenance haemodialysis.
Materials and methods: The study involved 100 participants, with an average age of 61.41 years (SD +/- 8.54), and a male preponderance of 5:1, comprising 80 male and 20 female participants. The majority of patients experienced conditions such as anaemia, atherosclerosis, infection, renal disease, hypertension, and diabetes mellitus. Among the 310 total prescriptions, antihypertensive medications were the most commonly prescribed, followed by antacids. Medications addressing comorbidities associated with chronic kidney disease were also prescribed, totalling 310 medications. For 59.05% of the drugs, dosage modification was unnecessary. Among the medications requiring dose adjustments, 72.66% were correctly adjusted, while 26 .66% were not.
Conclusion: According to the American Academy of Family Physicians, 73.87% of cases involving kidney cancer and hypertension included inappropriate drug prescriptions. This implies that, despite the fact that only 24% of medications were prescribed under their generic names, inappropriate prescribing remains a major concern at our hospital.
References
2. Singh AK, Farag YM, Mittal BV, Subramanian KK, Reddy SR, et al. (2013) Epidemiology and risk factors of chronic kidney disease in India - results from the SEEK (Screening and Early Evaluation of Kidney Disease) study. BMC Nephrol 14: 1471-2369.
3. Ruggenenti P, Schieppati A, Remuzzi G: Progression, remission, regressionof chronic renal diseases. Lancet 2001. 357(9268):1601–8.
4. Manley HJ, Drayer DK, Muther RS. Medication-related problem type and appearance rate in ambulatory hemodialysis patients. BMC Nephrol. 2003; 4:10.
5. Kappel J, Calissi P. Safe drug prescribing for patients with renal insufficiency. Can Med Assoc J. 2002;166:473-7.
6. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med. 2001;134:629-36.
7. Modi GK, Jha V: The incidence of end-stage renal disease in India: apopulation-based study. Kidney Int. 2006, 70(12):2131–3.
8. Kher V: End-stage renal disease in developing countries. Kidney Int .2002,62(1):350–62.
9. Rajapurkar MM, John GT, Kirpalani AL, Abraham G, Agarwal SK, et al. (2012) What do we know about chronic kidney disease in India: first report of the Indian CKD registry. BMC Nephrol. 13: 1471-2369.
10. Agarwal S, Srivastava R (2009) Chronic kidney disease in India: challenges and solutions. Nephron ClinPract. 111: c197-c203.
11. Couser WG, Remuzzi G, Mendis S, Tonelli M. The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney Int [Internet]. 2011 Dec;80(12):1258–70. Available from:
http://linkinghub.elsevier.com/retrieve/pii/S0085253815550047
12. Perazella MA. Renal Vulnerability to Drug Toxicity. Clin J Am SocNephrol [Internet]. 2009 Jul 1; 4(7):1275–83. Available from:
http://cjasn.asnjournals.org/cgi/doi/10.2215/CJN.02050309
13. Dasari P, Venkateshwarlu K, Venisetty RAJK. Management of Comorbidities in Chronic Kidney Disease : a Prospective Observational Study. Int J Pharm Pharm Sci. 2014;6(2):2–6.
14. Seck SM, Doupa D, Gueye L, AbdouDia C. Prevalence ofChronic Kidney Disease and Associated Factors in Senegalese Populations: A Community-Based Study in Saint-Louis. Nephrourol Mon [Internet]. 2014 Sep 5;6(5). Available from: http://www.numonthly.com/?page=article&article_id=19085.
15. Vela XF, Henríquez DO, Zelaya SM, Granados D V, Hernández MX, OrantesCM. Chronic kidney disease and associated risk factors in two Salvadoran farming communities, 2012. MEDICC Rev [Internet]. 2014 Apr;16(2):55–60. Available from: http://www.ncbi.nlm.nih.gov/ pubmed/24878650.
16. Fraser SDS, Roderick PJ, May CR, McIntyre N, McIntyre C, Fluck RJ, et al. The burden of comorbidity in people with chronic kidney disease stage 3: a cohort study.BMCNephrol [Internet]. 2015 Dec 1;16(1):193. Available from: http://www.biomedcentral.com/1471-2369/16/193.
17. Dasari P, Venkateshwarlu K, Venisetty RAJK. Management of Comorbidities in Chronic Kidney Disease : a Prospective Observational Study. Int J Pharm Pharm Sci. 2014;6(2):2–6.
18. Chang Y, Huang S, Tao P, Chien C. A population-based study on the association between acute renal failure (ARF) and the duration of polypharmacy. BMC Nephrol[Internet]. 2012 Dec 30;13(1):96. Available from:http://bmcnephrol.biomedcentral.com/articles/10.1186/1471-2369-13-96.
19. Pluguez-Turull CW, Jiménez V. Drug interactions in an elderly patient with significant polypharmacy: A Case study.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Parameshwari. K
Associate Professor St Peter's Medical college Hospital and Research Institute Hosur- 635109, Tamilnadu, India.
Malini S
Assistant Professor, Dept of anaesthesiology, Mysore Medical College and Research Institute
Mysuru-570001, Karnataka, India.
Varnit Kaushik
Senior resident. Department of Pharmacology. All India institute of medical sciences. New Delhi- 110608 India.
Purushotham. K.
Associate, Professor, Department of Pharmacology, Chamarajanagar Institute of Medical Sciences. Chamarajanagar- 571313, Karnataka, India.